NeuroVive Pharmaceutical AB (NVP) Jumped 0.57% on Dec 8

December 8, 2017 - By Michael Collier

Shares of NeuroVive Pharmaceutical AB (STO:NVP) last traded at 3.5, representing a move of 0.57%, or 0.02 per share, on volume of 95,920 shares. After opening the trading day at 3.41, shares of NeuroVive Pharmaceutical AB traded in a close range. NeuroVive Pharmaceutical AB currently has a total float of 52.33M shares and on average sees 235,058 shares exchange hands each day. The stock now has a 52-week low of 3.3 and high of 7.9.

Getting To Know The OMXS30

Sweden is a uniquely powerful economy in Europe just like Germany, France, and other thriving European economies. Its rich equity market is a proof of its excellent corporate governance that every investor is looking for when it comes to foreign investments. They are looking for NeuroVive Pharmaceutical AB to check its reliability.

The Swedish Equity Market

The Stockholm Stock Exchange, commonly known as Nasdaq Stockholm, is the main stock exchange in Sweden situated in Frihamnen, Stockholm. NeuroVive Pharmaceutical AB is one of the NASDAQ most active participants. It is operated by Nasdaq Nordiq, a 13-year-old subsidiary of Nasdaq, Inc.

Nasdaq Nordiq was established in 2003 for the primary purpose of overseeing the stock exchanges in Nordic countries. Aside from the Nasdaq Stockholm, it also operates the Tallinn Stock Exchange, commonly known as Nasdaq Baltic; the Riga Stock Exchange, commonly known as Nasdaq Baltic; the Iceland Stock Exchange, commonly known as Nasdaq Iceland; the Helsinki Stock Exchange, commonly known as Nasdaq Helsinki; the Copenhagen Stock Exchange, commonly known as Nasdaq Copenhagen; and the Armenia Stock Exchange, commonly known as Nasdaq OMX Armenia.

The Nasdaq Stockholm has been present since 1863, making it one of the oldest European stock exchanges. It has only adopted electronic trading on June 1, 1990. Prior to this, floor trading had happened at the Stockholm Stock Exchange Building.

The regular session on the Nasdaq Stockholm commences from 9:00 a.m. until 5:00 p.m. every business day. That is the time for NeuroVive Pharmaceutical AB to count its gain.

The OMX Stockholm 30 Index (OMXS30) is the market-capitalization-weighted index that monitors the 30 most active stocks on the Nasdaq Stockholm. Numerous sectors make up the OMXS30; and the top three largest sectors are Industrials, Financials, and Consumer Services. Being the benchmark index in Sweden, it is a crucial indicator of the Swedish economy.

The OMXS30 is rebalanced twice a year, ensuring a strong indication of how well the Swedish equity market is. As such, some components may be dropped to give way to other companies that are more competitive. Several factors such as liquidity, market capitalization, and industry representation play major role in a stock’s inclusion to the OMXS30.

By the Numbers

As of the end of the first quarter of 2016, the Nasdaq Stockholm has a market capitalization of nearly $1.30 trillion with over 300 stocks listed on it.

Meanwhile, the OMXS30 holds an all-time low of 98.86 points, which was last seen in November 1987. Sweden is one of the many countries that had suffered from Black Monday, a remarkable global equity market meltdown in history that began with the sinking of stocks on the Stock Exchange of Hong Kong (HK).

Gradually, the Swedish economy was able to overcome all other challenges through the years. In April 2015, the OMXS30 had reached an all-time high of 1,719.93 points.

The Nasdaq Stockholm is one of the most valuable and most competitive stock exchanges in Europe. Because of an attractive borrowing environment in European Union (EU) countries such as Sweden, many investors are flocking the Swedish equity market. There is no better way to take advantage of these growth opportunities than to invest in European stocks such as those listed on the Nasdaq Stockholm. And look for NeuroVive Pharmaceutical AB advantages.

More notable recent NeuroVive Pharmaceutical AB (STO:NVP) news were published by: which released: “Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)” on November 30, 2017, also with their article: “NeuroVive Pharmaceutical AB Year End Report January – December 2016” published on February 21, 2017, published: “NeuroVive Pharmaceutical AB Publishes 2016 Annual Report” on March 23, 2017. More interesting news about NeuroVive Pharmaceutical AB (STO:NVP) were released by: and their article: “Neurovive Pharmaceutical: NeuroVive and Arbutus Sign Termination Agreement” published on October 21, 2016 as well as‘s news article titled: “NeuroVive Pharmaceutical AB Interim Report January – March 2017” with publication date: May 18, 2017.

NeuroVive Pharmaceutical AB engages in the research, discovery, and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. The company has market cap of $183.14 million. The Company’s product portfolio includes NeuroSTAT, a drug candidate that is in Phase II clinical study for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test. It currently has negative earnings. The firm is also developing NVP015 for congenital mitochondrial disorders; NVP025 mitochondrial myopathies program; NV556 for the treatment of mitochondrial myopathy; NVP022 for targeting mitochondrial metabolic pathways in non-alcoholic steatohepatitis (NASH) and complementing NV556 in the treatment of NASH; and NVP024, a hepatocellular carcinoma program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.